SCHEMBL7781869

SCHEMBL7781869

COOc1ccc(O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.54
ESR2 Q92731 2/20 0.54
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ESR1 P03372 1/20 0.52
APP P05067 2/20 0.48
CALM1 P0DP23 1/20 0.45
GAA P10253 1/20 0.45
PKM P14618 1/20 0.45
LMNA P02545 2/20 0.44
TYR P14679 2/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
GMNN O75496 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10784953 0.85 CA1 (0.50) LTA4HMEN1KMT2AGAACA12
SCHEMBL20243981 0.83 PKM (0.72) LTA4HESR2GAAPKMLMNA
SCHEMBL1191086 0.82 ESR2 (0.65) LTA4HESR2MEN1KMT2AESR1
Mequinol SCHEMBL21009 0.77
1,4-Dimethoxybenzene SCHEMBL8351066 0.77 ESR2 (0.84) LTA4HESR2MEN1KMT2AESR1
Mequinol SCHEMBL166535 0.77 ESR2 (0.84) LTA4HESR2MEN1KMT2AESR1
SCHEMBL433779 0.77 CA1 (0.69) LTA4HESR2MEN1KMT2AGAA
Mequinol SCHEMBL1535640 0.77 ESR2 (0.84) LTA4HESR2MEN1KMT2AESR1
Hydroquinone SCHEMBL21010 0.75 CYP3A4 (0.67) LTA4HESR2MEN1KMT2AESR1
Hydroquinone SCHEMBL756935 0.75 CYP3A4 (0.67) LTA4HESR2MEN1KMT2AESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4423068-A1 RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-09-04 EP disclosed
WO-2023077070-A1 RXFP1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-04 WO disclosed
WO-2022077823-A1 APPLICATION OF MILOXACIN IN PREPARATION OF DRUG FOR TREATING AND/OR PREVENTING DISEASE TAKING T-TYPE CALCIUM CHANNEL AS THERAPEUTIC TARGET 苏州大学 2022-04-21 WO disclosed
CN-111655662-A Compound, resin, composition, resist pattern forming method, circuit pattern forming method, and resin purifying method 三菱瓦斯化学株式会社 2020-09-11 CN disclosed
US-20120052440-A1 SALT AND PHOTORESIST COMPOSITION COMPRISING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-03-01 US disclosed
US-20110318690-A1 COMPOUND, RESIN AND PHOTORESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-29 US disclosed
US-20110236827-A1 RESIN AND PHOTORESIST COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-29 US disclosed
US-20110165513-A1 PHOTORESIST COMPOSITION SUMITOMO CHEMICAL COMPANY LTD (JP) 2011-07-07 US disclosed
US-20110059400-A1 PHOTORESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-03-10 US disclosed
US-20110046362-A1 METHODS OF MAKING NUCLEOSIDE TETRAPHOSPHATE MICRODOSE THERAPEUTX, INC. 2011-02-24 US disclosed
EP-0746306-B1 BENZOYLACETATE ESTERS AS NON-SENSITIZING CHELATING PHOTO-PROTECTANTS PROCTER & GAMBLE (US) 2001-11-07 EP disclosed
US-4961870-A CLEANING, DEGREASING, SOLVENTS ALLIED-SIGNAL INC. (US) 1990-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052440-A1 SALT AND PHOTORESIST COMPOSITION COMPRISING THE SAME C1S, C1R, CLIC1 LTA4H 4198/4885ESR2 2342/4885MEN1 1232/4885
US-20110059400-A1 PHOTORESIST COMPOSITION C1R, C1S, CCNT1 LTA4H 357/4885ESR2 1167/4885MEN1 1989/4885
US-20110046362-A1 METHODS OF MAKING NUCLEOSIDE TETRAPHOSPHATE P2RY1, P2RY6, NUDT1 LTA4H 271/4885ESR2 4468/4885MEN1 3173/4885
US-20110236827-A1 RESIN AND PHOTORESIST COMPOSITION CONTAINING THE SAME C1R, CBR1, RCOR1 LTA4H 950/4885ESR2 382/4885MEN1 3660/4885
US-20110318690-A1 COMPOUND, RESIN AND PHOTORESIST COMPOSITION RCOR1, C1R, C1S LTA4H 2506/4885ESR2 684/4885MEN1 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.